This site is for customers in Asia. Customers in China & other regions, please go to Global page.
HOME > Product category > Autophagy > Antibodies against p62/SQSTM1

Antibodies against p62/SQSTM1


  • p62/SQSTM1 is considered to be the substrate that binds directly to LC3 causing its selective degradation by autophagy.
  • Anti-p62/SQSTM1 antibodies, which have a variety of applications including Western blotting (WB), immunoprecipitation (IP), Immunocytochemistry (IC), and immunohistochemistry (IHC), are useful for observation of p62-caused pathogenesis and dynamics at the molecular level.

p62/SQSTM1 is considered to be the substrate that binds directly to LC3 causing its selective degradation by autophagy. Anti-p62/SQSTM1 antibody, which has a variety of applications including Western blotting (WB), immunoprecipitation (IP), immunocytochemistry (IC), and immunohistochemistry (IHC), is useful for observation of p62-caused pathogenesis and dynamics at the molecular level.

The ubiquitin-conjugating protein p62/SQSTM1 is thought to be a scaffold protein because it interacts with a variety of molecules involved in toll-like receptor (TLR) signaling, such as TRAF6, ERK, and aPKC. Recent evidence shows that p62 binds directly to the autophagosome marker LC3 and then is selectively degraded by autophagy. Actually, in liver- or brain-specific autophagy-defective mice, excessive p62 accumulation leads to formation of ubiquitin- and p62-positive inclusions. Importantly, ubiquitin- and p62-positive inclusions have been detected in tissues from patients with neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis), alcoholic hepatitis, fatty liver, or liver cancer.

Currently, the association of autophagy-induced p62 metabolic failure with the pathogenesis of these diseases is an important focus of attention.

  • Komatsu M, et al: J Cell Biol (2005) 169: 425-434
  • Komatsu M, et al: Nature (2006) 441: 880-884
  • Hara T, et al: Nature (2006) 441:885-889
  • Komatsu M, et al.:Cell (2007) 131:1149-63


Immunocytochemistry



In the starved cells, p62 is stained as dots.



Western blotting



Immunoprecipitation





Immunohistochemistry



Rate of p62-positive inclusion bodies in the Human liver carcinoma by staining with Anti-p62 antibody

(Summarized results of staining with HUMAN liver array by Shanghai Outdo Biotech)

  Human liver carcinoma (n=32) Human normal liver (n=4)
cytoplasmic staining (+)
inclusion body staining (+)
22 (69%) 0 (0%)
cytoplasmic staining (+)
inclusion body staining (-)
8 (25%) 0 (0%)
cytoplasmic staining (-)
inclusion body staining (-)
2 (6%) 4 (100%)

In the Human liver carcinoma, p62-positive inclusion bodies were observed in 69 % (22 out of 32) of the tested samples. In the norma Human liver, p62-positive staining were not observed.





Pick Up products